Guidelines for Authors
www.karger.com/ocl_guidelines
 Submission
Conditions
Conflicts of Interest
Ethical and Legal Prerequisites
Categories of Manuscripts
Arrangement
Color Illustrations
References
Digital Object Identifier (DOI)
Author's ChoiceTM, NIH-Funded Research, Self-Archiving
Page Charges
Proofs
Reprints
Submission
Original papers and reviews written in English are considered for publication. Manuscripts should be submitted to ‘Oncology’ online.
For specific instructions on how to prepare a manuscript for submission please visit:
Names, postal and e-mail addresses of at least four experts in the appropriate area of
research must accompany each manuscript. Selected scientists will be invited to act as
referees. Referees suggested should not be from the same institution as the author and
should have expert knowledge of the subject.
Should you have any problems with your submission, please contact:
Dr. Maurie Markman, MD
S. Karger AG
Editorial Office 'Oncology'
P.O. Box
CH–4009 Basel (Switzerland)
Tel. +41 61 306 1359
Fax +41 61 306 1434
E-Mail ocl@karger.ch
Mailing address for courier deliveries only:
Allschwilerstrasse 10
CH–4055 Basel (Switzerland)
Conditions
All manuscripts are subject to editorial review. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. The editors reserve the right to improve style and, if necessary, return the manuscript for rewriting to the author. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of ‘Oncology’ and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author’s responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications. All manuscripts originating from non-English speaking countries must be revised by a professional linguistic reviewer and it must be evident from the covering letter that this has been done.
The editor reserves the right to reject papers based on priorities and space availability in the journal.
Conflicts of Interest
Authors are required to disclose any sponsorship or funding arrangements relating to their research and all authors should disclose any possible conflicts of interest. Conflict of interest statements will be published at the end of the text of the article.
Ethical and Legal Prerequisites
Manuscripts involving examinations of human subjects must include a statement that the trial protocol has been approved by an ethical committee and thus meets the standards of the Declaration of Helsinki in its revised version of 1975 and its amendments of 1983, 1989, and 1996 [JAMA 1997;277:925-926]. Accordingly, the subject's informed consent has to be mentioned in the manuscript. Information suitable to reveal the subject's identity is to be avoided.
Categories of Manuscripts
Reviews are comprehensive, state-of-the-art analyses and investigations of important clinical problems. Reviews may be invited by the Editor, or they may be unsolicited submissions. Reviews are not subject to page charges. The maximum length of manuscripts in this category will be 5,000 words for text and tables (a table = 250 words, per page), with a maximum of 5 tables and 50 references.
Clinical Studies and Clinical Translational Research Articles are full-length research papers which will be considered for the journal. These articles cover topics relevant to clinical and translational studies in all oncological fields. Note that manuscripts presenting laboratory-based research efforts must address a clinically relevant issue (Translational Research).
Short Communications will focus on descriptions of important toxicities of novel therapies and highly unique oncology-related medical management issues. The maximum length of manuscripts in this category will be 1,000 words.
Clinical Trial Notes are designed for brief discussions of clinical trials, with a particular focus on phase 1, phase 1/2, and phase 2 studies. Priority in this section will not be for studies with a ‘positive result’, but rather for well-conceived and conducted clinical research efforts. The maximum length of manuscripts submitted in this category will be 1,500 words, with a maximum of 2 tables and 1 figure. The paper should be divided into four sections: Introduction, Methods, Results, Discussion. Note that all manuscripts submitted in this category will undergo rapid review for acceptance or rejection.
Reducing the Worldwide Burden of Cancer are country reports describing a variety of regional, national or international efforts that focus on the unique aspects of the epidemiology of cancer, and the delivery of educational messages, preventive services, and oncology-related care within the developing world. Papers submitted for this section benefit from a higher quota of free pages. There are no page charges for papers of 8 or fewer printed pages. Each additional complete or partial page is charged to the author at CHF 310.00.
Editorials provide comments on papers published in Oncology. They are usually invited by the Editor.
Arrangement
Title page: The first page of each paper should indicate the title, the authors’ names, the institute where the work was conducted, and a short title for use as running head.
NB: Authors wishing to preserve the phonetic meaning of diacritics (PubMed reduces diacritics to their root characters) must spell their names accordingly when submitting manuscripts (e.g. Müller should be Mueller).
Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail address.
Key words: For indexing purposes, every submission is required to list 3–10 key words.
Abstract: Papers submitted to the sections Reviews, Clinical Studies, Clinical Translational Research Articles, Clinical Trial Notes and Reducing the Worldwide Burden of Cancer need an abstract of up to 200 words. Abstracts are recommended, but optional, for Short Communications and Editorials. Abstracts of papers submitted for publication that have clinical implications using human materials should be structured with subheadings as follows: Objective(s), Methods, Results, Conclusion(s).
Footnotes: Avoid footnotes. When essential, they are numbered consecutively and typed at the foot of the appropriate page.
Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate pages. Tables require a heading and figures a legend, also prepared on a separate page. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size 180 x 223 mm) or provide crop marks. Each illustration must be labelled with its number and the first author’s name.
B/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi. Figure files must not be embedded in a document file but submitted separately (see also the detailed Online Submission Instructions).
Color Illustrations
Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.
Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 760.00 per page.
References
In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as 'unpublished data' and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. (Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals. N Engl J Med 1997;336:309–315 www.icmje.org)
|
Examples
(a) Papers published in periodicals:
Chatel J-M, Bernard H, Orson FM: Isolation and characterization of two complete Ara h 2 isoforms cDNA. Int Arch Allergy Immunol 2003;131:
14–18.
(b) Papers published only with DOI numbers:
Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.
(c) Monographs:
Matthews DE, Farewell VT: Using and Understanding Medical Statistics,
ed 3, revised. Basel, Karger, 1996.
(d) Edited books:
Cochrane AL, Ricardo SD: Oxidant stress and regulation of chemokines in the development of renal interstitial fibrosis; in Razzaque MS, Taguchi T (eds): Renal Fibrosis. Contrib Nephrol. Basel, Karger, 2003, vol 139,
pp 102–119.
|
Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.
Digital Object Identifier (DOI)
S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org
Author's ChoiceTM
Karger's Author's ChoiceTM service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.Karger.com. The option is available for a one-time fee of CHF 2,750.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.
NIH-Funded Research
The U.S. National Institutes of Health (NIH) mandates under the NIH Public Access Policy that final, peer-reviewed manuscripts appear in its digital database within 12 months of the official publication date. As a service to authors, Karger submits the final version of your article on your behalf to PubMed Central. For those selecting our premium Author's ChoiceTM service, we will send your article immediately upon publishing, accelerating the accessibility of your work without the usual embargo. More details on NIH's Public Access Policy is available here.
Self-Archiving
Karger permits authors to archive their pre-prints (i.e. pre-refereeing) or post-prints (i.e. final draft post-refereeing) on their personal or institution's servers, provided the following conditions are met: Articles may not be used for commercial purposes, must be linked to the publisher's version, and must acknowledge the publisher's copyright. Authors selecting Karger's Author's ChoiceTM feature, however, are also permitted to archive the final, published version of their article, which includes copyediting and design improvements as well as citation links.
Page Charges
There are no page charges for papers of 3 or fewer printed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author CHF 310.00. The allotted size of a paper is equal to approx. 9 manuscript pages (including tables, illustrations and references).
Proofs
Unless indicated otherwise, proofs are sent to the first-named author and should be returned with the least possible delay. Alterations made in proofs, other than the correction of printer’s errors, are charged to the author. No page proofs are supplied.
Reprints
Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.
|
|
|
| Search in this journal
|
|
|
|
For non-native English speakers and international authors who would like assistance with their writing before submission, we suggest American Journal Experts for their scientific editing service. |
|
|
Online Manuscript Submission
Guidelines
